Tolerating DHODH

How Immunic plans to differentiate its oral DHODH inhibitor in IBD

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the clinic for Crohn’s disease.

Inflammatory bowel diseases such as Crohn’s and ulcerative colitis are caused by over-reactive immune responses in the gut mediated by T helper type 1 (Th1) and Th17 cells, which rapidly divide and secrete the cytokines interferon

Read the full 745 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE